Summary:
This study is looking for participants diagnosed with type 2 Diabetes Mellitus (DMII). Participants with an hbA1c between 7-10% and who are taking a GLP-1 for their diabetes control may qualify to take part in this study. The study is looking into the efficacy and safety of a combo injectable, Icosema, treatment to control Type 2 Diabetes Mellitus (DMII) versus Semaglutide (Ozempic).
Qualified Participants Must:
• Diagnosed with type 2 diabetes mellitus
•
Have an hbA1c of 7-10%
•
18+ years of age
•
Taking a GLP-1 for diabetes control
Qualified Participants May Receive:
Those who qualify may be eligible for compensation for time and travel, patients who qualify will receive $75 per in-office visit and $15 per phone call.